Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIFENSE: Difamilast Early Intervention in Infantile Atopic Dermatitis
jRCTs031240529Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of difamilast in atopic dermatitis (AD) and food allergy (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary sensitization endpoint at 16 weeks. Started May 2025; status: recruiting.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)food allergy
Beyond the preview
Go deeper on jRCTs031240529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240529.